Serial No:

PCT/US03/020410

Filed: 2

27 June 2003

10/518868 DT01 Rec'd PCT/PTC 17 DEC 2004

In the Claims:

Please cancel claims 1-15 and 27-40 without prejudice and subject to being re-asserted at a later time.

Please amend the claims to read as follows:

1-15. (Canceled)

- 16. (Original) A method for identifying an agent that modulates a Gene95 activity, comprising:
- a) contacting a test compound with a polypeptide encoded by a polynucleotide corresponding to *gene95* under conditions supporting an activity of said polypeptide; and
- b) determining a change in the activity of the polypeptide as a result of said contacting;

wherein said change in activity identifies the test compound as an agent that modulates a Gene95 activity.

- 17. (Original) The method of claim 16 wherein the determined change in activity in step (b) is a decrease in activity.
- 18. (Original) The method of claim 16 wherein the determined change in activity in step (b) is an increase in activity.
- 19. (Original) The method of claim 16 wherein the activity is measured by measuring the activity of an enzyme.
- 20. (Original) The method of claim 16 wherein the polypeptide is present in a lipid bilayer.
- 21. (Original) The method of claim 20 wherein the lipid bilayer is part of a liposome.

Serial No: PCT/US03/020410

Filed: 27 June 2003

22. (Original) The method of claim 16 wherein the polypeptide is part of an intact cell.

- 23. (Original) The method of claim 22 wherein the intact cell is a cell that has been engineered to comprise said polypeptide.
- 24. (Original) The method of claim 22 wherein the intact cell is a recombinant cell that has been genetically engineered to express said polypeptide.
- 25. (Original) The process of claim 24 wherein the cell does not express said polypeptide absent said engineering.
 - 26. (Original) The process of claim 22 wherein said cell is a mammalian cell.
 - 27-40. (Canceled)
- 41. (Original) An isolated polynucleotide comprising a polynucleotide sequence or the full complement of the polynucleotide sequence, wherein the polynucleotide sequence is at least 95% identical to SEQ ID NO: 3.
- 42. (Original) An isolated polynucleotide comprising a polynucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 4.
- 43. (Original) An isolated polynucleotide comprising a polynucleotide that has the sequence set forth in SEQ ID NO: 3.
- 44. (Original) An isolated polypeptide comprising an amino acid sequence having at least 95% identity with the amino acid sequence set forth in SEQ ID NO: 4.

Serial No: PCT/US03/020410

Filed: 27 June 2003

45. (Original) The isolated polypeptide of claim 44, wherein the isolated polypeptide comprises an the amino acid sequence having at least 95% identity with the amino acid sequence set forth in SEQ ID NO: 4.

- 46. (Original) An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 4.
- 47. (Original) An isolated polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 4.
- 48. (Original) A nucleic acid vector comprising the isolated polynucleotide of claim 41.
 - 49. (Original) A recombinant host cell comprising the vector of claim 48.
- 50. (Original) A method for producing the polypeptide of SEQ ID NO: 4 comprising culturing the host cell of claim 49 under conditions supporting production of the polypeptide.